🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,328 results for “Xiyuan Hospital of China Academy of Chinese Medical Sciences” Clear

  1. PEGylated recombinant human interferon alpha-2b injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis B, Chronic

    phase 1 small molecule active

    1 trial

  2. Pyrotinib low dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  3. QLS32015

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 1 mab active

    1 trial

  4. QN-023a

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML, Adult

    phase 1 small molecule terminated

    1 trial

  5. QT-019C

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    SLE - Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  6. RD13-02

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Severe Aplastic Anemia

    phase 1 mab active

    1 trial

  7. RJMty19 (CD19-CAR-DNT cells)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  8. Rapamycin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Graves Ophthalmopathy

    phase 1 small molecule active

    1 trial

  9. Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 1 mab completed

    1 trial

  10. Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Carcinoma

    phase 1 small molecule completed

    1 trial

  11. SIBP-A13 formulation for injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  12. SYS6055

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-Cell Malignancies

    phase 1 small molecule active

    1 trial

  13. Sanchi-Tongshu Capsule (Enteric coated pellets)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy

    phase 1 small molecule completed

    1 trial

  14. Sapropterin dihydrochloride tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule active

    1 trial

  15. Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  16. Single dose intravenous injection of BBM 002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hemophilia A

    phase 1 gene therapy active

    1 trial

  17. Sup19 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  18. T3011

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Ascites

    phase 1 small molecule active

    1 trial

  19. TH-SC01(Umbilical cord mesenchymal stem cells)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Injury

    phase 1 mab active

    1 trial

  20. Ta-NPs (2% Tumor Volume)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Recurrent Retroperitoneal Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  21. Tamsulosin formulation-A

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy

    phase 1 small molecule completed

    1 trial

  22. Target CD7 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  23. Tetrahydrobiopterin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation-Induced Dermatitis

    phase 1 small molecule active

    1 trial

  24. The 10mg dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources